Develops yttrium-90 based devices for treating solid tumors in humans and animals.
Jun 2026Revenue $99.1K/yrExpenses $2.93M/yr
No trend
Figures by year
When will Vivos be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $99.1K and expenses $2.93M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $68.4K | $3.23M | −$3.17M |
| Dec 2024 | $28.0K | $2.63M | −$2.60M |
| Dec 2023 | $19.5K | $2.81M | −$2.79M |
| Dec 2022 | $36.5K | $2.55M | −$2.52M |
| Dec 2021 | $14.9K | $2.52M | −$2.50M |
| Dec 2020 | $7.00K | $680K | −$673K |
| Dec 2019 | $9.50K | $1.34M | −$1.33M |
| Dec 2017 | $4.05K | $2.62M | −$2.62M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.